Current Clinical Trials

Hematologic oncology, hematological, Bleeding & Thrombotic Disorders research

 

To inquire about benign or malignant hematology ongoing clinical trials, please reach the clinical research team on 01-350000 Ext: 5110,  7804 or 7803

 

For trials involving Dr. Bazarbachi please reach Ext: 7090/1

For international clinical trials on malignant hematology or blood cancers, please check the following link: https://clinicaltrials.gov/

 

Ongoing benign hematology clinical research projects:

 

Benign hematology

 

 PI: Dr. Ali Taher

• A Phase 2, Double-Blind, Randomized, Placebo Controlled, Multicenter Study to Determine the efficacy and Safety of Luspatercept (Ace-536) Versus placebo In adults With Non Transfusion Dependent Beta (β)-Thalassemia (the BEYOND Study) (ACE-536-B-THAL-002)

 

• A phase 3B, Open-Label, Single-Arm, Rollover study to evaluate long-term safety in subjects who have participated in other LUSPATERCEPT (ACE-536) clinical trials. (ACE-536-LTFU-001)

 

• Randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance and change in serum ferritin of a deferasirox granule formulation in children and adolescents with any transfusion-dependent anemia requiring chelation therapy due to iron overload (CICL670F2202)

 

• Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease (IMR-SCD-301)

 

• A phase 2 study to evaluate the safety and tolerability of IMR-687 in subjects with Beta-Thalassemia (IMR-BTL-201)

 

• A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Patients with Non-Transfusion Dependent β-Thalassemia Intermedia (ISIS 702847)

 

• A Prospective, Multicentre, Non-Interventional Study Evaluating the Bleeding Incidence in Patients with Von Willebrand Disease Undergoing On-Demand Treatment (WIL-29)

 

• Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with VWD (WIL-31)

 

• A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients (CINC424H12201-ADORE)

 

• A Phase 2a, double-blind, randomized, placebo-controlled ascending dose and maintenance dose safety and efficacy study of multiple doses of VIT-2763 in subjects with sickle cell disease

 

PI: Dr. Iman Abou Dalle

 

• STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

 

• A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients

 

• Randomized dasatinib 50 vs 100 mg in chronic myeloid leukemia

 

Ongoing malignant hematology clinical research projects:

 

Malignant hematology & stem cell transplant research

 

PI: Dr. Jean el Cheikh:

• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

 

PI: Dr. Ali Bazarbachi:

• A phase 3, multicenter, open-label, randomized study of oral ABL001 versus bosutinib in patients with chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors (CABL001A2301)

 

• Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia (LPI-JOR-LEB-KSA-TUN-2017-01)

 

• A randomized, double-blind, placebo-controlled phase III multi-center study of Azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)”. IRB ID: CMBG453B12301/BIO-2020-0171.